556 related articles for article (PubMed ID: 26656783)
1. Efficacy and tolerability of adjunct perampanel based on number of antiepileptic drugs at baseline and baseline predictors of efficacy: A phase III post-hoc analysis.
Glauser T; Laurenza A; Yang H; Williams B; Ma T; Fain R
Epilepsy Res; 2016 Jan; 119():34-40. PubMed ID: 26656783
[TBL] [Abstract][Full Text] [Related]
2. Perampanel efficacy and tolerability with enzyme-inducing AEDs in patients with epilepsy.
Gidal BE; Laurenza A; Hussein Z; Yang H; Fain R; Edelstein J; Kumar D; Ferry J
Neurology; 2015 May; 84(19):1972-80. PubMed ID: 25878177
[TBL] [Abstract][Full Text] [Related]
3. Concentration-effect relationships with perampanel in patients with pharmacoresistant partial-onset seizures.
Gidal BE; Ferry J; Majid O; Hussein Z
Epilepsia; 2013 Aug; 54(8):1490-7. PubMed ID: 23772853
[TBL] [Abstract][Full Text] [Related]
4. Analysis of pooled phase III trials of adjunctive perampanel for epilepsy: Impact of mechanism of action and pharmacokinetics on clinical outcomes.
Kwan P; Brodie MJ; Laurenza A; FitzGibbon H; Gidal BE
Epilepsy Res; 2015 Nov; 117():117-24. PubMed ID: 26448264
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305.
French JA; Krauss GL; Steinhoff BJ; Squillacote D; Yang H; Kumar D; Laurenza A
Epilepsia; 2013 Jan; 54(1):117-25. PubMed ID: 22905857
[TBL] [Abstract][Full Text] [Related]
6. Final safety, tolerability, and seizure outcomes in patients with focal epilepsy treated with adjunctive perampanel for up to 4 years in an open-label extension of phase III randomized trials: Study 307.
Krauss GL; Perucca E; Kwan P; Ben-Menachem E; Wang XF; Shih JJ; Patten A; Yang H; Williams B; Laurenza A
Epilepsia; 2018 Apr; 59(4):866-876. PubMed ID: 29574701
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies.
Steinhoff BJ; Ben-Menachem E; Ryvlin P; Shorvon S; Kramer L; Satlin A; Squillacote D; Yang H; Zhu J; Laurenza A
Epilepsia; 2013 Aug; 54(8):1481-9. PubMed ID: 23663001
[TBL] [Abstract][Full Text] [Related]
8. Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304.
French JA; Krauss GL; Biton V; Squillacote D; Yang H; Laurenza A; Kumar D; Rogawski MA
Neurology; 2012 Aug; 79(6):589-96. PubMed ID: 22843280
[TBL] [Abstract][Full Text] [Related]
9. A multivariable prediction model of a major treatment response for focal-onset seizures: A post-hoc analysis of Phase III trials of perampanel.
Krauss GL; Ben-Menachem E; Wechsler RT; Patten A; Williams B; Laurenza A; Malhotra M
Epilepsy Res; 2021 Aug; 174():106649. PubMed ID: 34022524
[TBL] [Abstract][Full Text] [Related]
10. [Perampanel in treatment of refractory partial epilepsy in adolescents and adults: results of international multicenter randomized, double-blind, placebo-controlled phase III studies].
Belousova ED
Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(8):32-8. PubMed ID: 25345628
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics, exposure-cognition, and exposure-efficacy relationships of perampanel in adolescents with inadequately controlled partial-onset seizures.
Villanueva V; Majid O; Nabangchang C; Yang H; Laurenza A; Ferry J; Hussein Z
Epilepsy Res; 2016 Nov; 127():126-134. PubMed ID: 27595590
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of adjunctive perampanel in adolescent patients with epilepsy: Post hoc analysis of six randomized studies.
Piña-Garza JE; Rosenfeld W; Saeki K; Villanueva V; Yoshinaga H; Patten A; Williams B; Malhotra M
Epilepsy Behav; 2020 Mar; 104(Pt A):106876. PubMed ID: 31954998
[TBL] [Abstract][Full Text] [Related]
13. Absence of Liver Toxicity in Perampanel-Treated Subjects: Pooled results from partial seizure phase III perampanel clinical studies.
Laurenza A; Yang H; Williams B; Zhou S; Ferry J
Epilepsy Res; 2015 Jul; 113():76-85. PubMed ID: 25986193
[TBL] [Abstract][Full Text] [Related]
14. Long-term effects of adjunctive perampanel on cognition in adolescents with partial seizures.
Piña-Garza JE; Lagae L; Villanueva V; Renfroe JB; Laurenza A; Williams B; Kumar D; Meador KJ
Epilepsy Behav; 2018 Jun; 83():50-58. PubMed ID: 29653338
[TBL] [Abstract][Full Text] [Related]
15. Perampanel, a selective, noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: interim results from phase III, extension study 307.
Krauss GL; Perucca E; Ben-Menachem E; Kwan P; Shih JJ; Squillacote D; Yang H; Gee M; Zhu J; Laurenza A
Epilepsia; 2013 Jan; 54(1):126-34. PubMed ID: 22905878
[TBL] [Abstract][Full Text] [Related]
16. Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures.
Krauss GL; Serratosa JM; Villanueva V; Endziniene M; Hong Z; French J; Yang H; Squillacote D; Edwards HB; Zhu J; Laurenza A
Neurology; 2012 May; 78(18):1408-15. PubMed ID: 22517103
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of perampanel in adolescent patients with drug-resistant partial seizures in three double-blind, placebo-controlled, phase III randomized clinical studies and a combined extension study.
Rosenfeld W; Conry J; Lagae L; Rozentals G; Yang H; Fain R; Williams B; Kumar D; Zhu J; Laurenza A
Eur J Paediatr Neurol; 2015 Jul; 19(4):435-45. PubMed ID: 25823975
[TBL] [Abstract][Full Text] [Related]
18. Long-term tolerability, safety and efficacy of adjunctive perampanel in the open-label, dose-ascending Study 231 and extension Study 233 in Japanese patients with epilepsy.
Usui N; Akamatsu N; Nakasato N; Ohnishi A; Kaneko S; Hiramatsu H; Saeki K; Miyagishi H; Inoue Y
Seizure; 2018 Nov; 62():26-32. PubMed ID: 30267941
[TBL] [Abstract][Full Text] [Related]
19. Adjunctive perampanel in partial-onset seizures: Asia-Pacific, randomized phase III study.
Nishida T; Lee SK; Inoue Y; Saeki K; Ishikawa K; Kaneko S
Acta Neurol Scand; 2018 Apr; 137(4):392-399. PubMed ID: 29250772
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic Drug Monitoring for Perampanel in Japanese Epilepsy Patients: Influence of Concomitant Antiepileptic Drugs.
Yamamoto Y; Usui N; Nishida T; Takahashi Y; Imai K; Kagawa Y; Inoue Y
Ther Drug Monit; 2017 Aug; 39(4):446-449. PubMed ID: 28703720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]